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Abstract: The MAL gene encodes a 17-kDa protein containing four putative transmembrane segments
whose expression is restricted to human T cells, polarized epithelial cells and myelin-forming cells.
The MAL protein has two unusual biochemical features. First, it has lipid-like properties that qualify
it as a member of the group of proteolipid proteins. Second, it partitions selectively into detergent-
insoluble membranes, which are known to be enriched in condensed cell membranes, consistent
with MAL being distributed in highly ordered membranes in the cell. Since its original description
more than thirty years ago, a large body of evidence has accumulated supporting a role of MAL in
specialized membranes in all the cell types in which it is expressed. Here, we review the structure,
expression and biochemical characteristics of MAL, and discuss the association of MAL with raft
membranes and the function of MAL in polarized epithelial cells, T lymphocytes, and myelin-forming
cells. The evidence that MAL is a putative receptor of the epsilon toxin of Clostridium perfringens, the
expression of MAL in lymphomas, the hypermethylation of the MAL gene and subsequent loss of
MAL expression in carcinomas are also presented. We propose a model of MAL as the organizer
of specialized condensed membranes to make them functional, discuss the role of MAL as a tumor
suppressor in carcinomas, consider its potential use as a cancer biomarker, and summarize the
directions for future research.
Keywords: condensed membranes; membrane trafficking; toxins; epithelial cells; T cells; myelin-
forming cells; gene hypermethylation; cancer; MARVEL domain; biomarker
1. Introduction
The human MAL cDNA was originally identified during a search for genes that are
selectively expressed during T cell differentiation [1]. In addition to T cells, MAL gene
expression was detected in specific polarized epithelia and in myelin-forming cells [2–5].
The MAL gene encodes a highly hydrophobic integral membrane protein of 153 amino
acids that is conserved across vertebrates; approximately 53% and 69% of the residues in
human MAL are identical or similar, respectively, to those in zebrafish MAL. Structural
predictions suggest that MAL has a four transmembrane-helix architecture with its N- and
C-terminal ends oriented towards the cytoplasm (Figure 1A) [1].
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Figure 1. The human MARVEL superfamily of proteins. (A) Predicted structure of human MAL according to Uniprot 
(https://www.uniprot.org/uniprot/P21145, accessed on 5 April 2021). Protein segments: 1–24 cytoplasmic, 25–46 
transmembrane, 47–53 first extracellular loop, 54–75 transmembrane, 76–92 cytoplasmic loop, 93–114 transmem-
brane, 115–124 second extracellular loop, 126–147 transmembrane, 148–153 cytoplasmic. The human MAL sequence 
as well as that of other species in shown in Figure S1. The length of the different segments in the schematics is drawn 
to scale. (B) Tree of human MARVEL domain-containing proteins. The sequence of the indicated proteins except 
their cytoplasmic amino- and carboxyl-terminal tails was aligned using the Muscle algorithm of the Jalview software 
[6], and the resulting alignment was used in MegaX [7]. The protein accession numbers of the corresponding se-
quences were: CMTM1 (NP_443725.3), CMTM2 (NP_653274.1), CMTM3 (NP_653201.1), CMTM4 (NP_848933.1), 
CMTM5 (NP_612469.1), CMTM6 (NP_060271.1), CMTM7 (NP_612419.1), CMTM8 (NP_849199.2), CKLF 
(NP_058647.1, PLP2/A4 (NP_002659.1), MYADM (NP_612382.1), MYADML2 (NP_001138585.2), MAL 
(NP_002362.1), MAL2 (NP_443118.1), MALL/BENE (NP_005425.1), PLLP/plasmolipin (NP_057077.1), occludin 
(NP_002529.1), MARVELD2/tricellulin (NP_001033692.2), MARVELD3 (NP_443090.4), SYPH/synaptophysin 
(NP_003170.1), SYPL1/pantophysin (NP_006745.1), SYPL2/mitsugumin (NP_001035799.1), SYNPR/synaptoporin 
(NP_001123475.1), SNG1 (NP_004702.2), SNG2 (NP_004701.1), SNG3 (NP_004200.2) and SNG4 (NP_036583.2). (C) 
Two views of the three-dimensional structure proposed for the hexameric synaptophysin complex. The highlighted 
area represents the lipid bilayer. The transmembrane segments of the MARVEL domain are indicated. 
MAL shares significant sequence similarity in its four transmembrane domains 
with other integral membrane proteins. This allows the definition of a domain, called 
the MARVEL (MAL and related proteins for vesicle formation and membrane link) 
domain, that is present in 24 human proteins. These constitute the MARVEL super-
family and are conserved across species [8]. The MARVEL superfamily includes the 
CMTM (chemokine-like factor MARVEL transmembrane domain containing) [9], 
MAL [10,11], physin [12,13], and TAMP (tight junction-associated MARVEL) [14] 
families (Figure 1B). The MAL family consists of seven members. MAL2, 
MALL/BENE, PLLP and CMTM8 display a tetraspanning topology similar to that of 
MAL. The other two members, myeloid differentiation-associated marker (MYADM) 
and MYADM-like2 (MYADML2), contain an additional MARVEL domain and form 
an independent branch within the family. Synaptophysin, which is the most abun-
dant protein in synaptic vesicles [15], is the only MARVEL superfamily member 
whose 3D structure has been determined so far [16]. Synaptophysin adopts a hex-
americ basket-like complex with six spokes each, corresponding to a synaptophysin 
subunit, with an extended, open conformation on the vesicle lumen and a closed end 
containing the N- and C-termini on the cytosolic side of the vesicle membrane (Figure 
1C). This structure is consistent with the proposed role of synaptophysin as a com-
ponent of the fusion pore during synaptic vesicle exocytosis [17,18]. It is currently 
Figure 1. The human MARVEL superfamily of proteins. (A) Predicted structure of human MAL
according to Uniprot (https://www.uniprot.org/uniprot/P21145, accessed on 5 April 2021).
Protein segments: 1–24 cytoplasmic, 25–46 transmembrane, 47–53 first extracellular loop, 54–75
transmembrane, 76–92 cytoplasmic loop, 93–114 transmembrane, 115–124 second extracellular loop,
126–147 transmembrane, 148–153 cytoplasmic. The human MAL sequence as well as that of other
species in shown in Figure S1. The length of the different segments in the schematics is drawn to scale.
(B) Tree of human MARVEL domain-containi proteins. The sequence of the indicated proteins
except their cytoplasmic amino- and carboxyl-terminal tails was aligned using th Muscle algorithm
of the Jalview software [6], and the resulting alignment was used in MegaX [7]. The protein accession
numbers of the corresponding sequences were: CMTM1 (NP_443725.3), CMTM2 (NP_653274.1),
CMTM3 (NP_653201.1), CMTM4 (NP_848933.1), CMTM5 (NP_612469.1), CMTM6 (NP_060271.1),
CMTM7 (NP_612419.1), CMTM8 (NP_849199.2), CKLF (NP_058647.1, PLP2/A4 (NP_002659.1),
MYADM (NP_612382.1), MYADML2 (NP_001138585.2), MAL (NP_002362.1), MAL2 (NP_443118.1),
MALL/BENE (NP_005425.1), PLLP/plasmolipin (NP_057077.1), occludin (NP_002529.1),
MARVELD2/tricellulin (NP_001033692.2), MARVELD3 (NP_443090.4), SYPH/synaptophysin
(NP_003170.1), SYPL1/pantophysin (NP_006745.1), SYPL2/mitsugumin (NP_001035799.1),
SYNPR/synaptoporin (NP_001123475.1), SNG1 (NP_004702.2), SNG2 (NP_004701.1), SNG3
(NP_004200.2) and SNG4 (NP_036583.2). (C) Two views of the three-dimensional structure proposed
for the hexameric synaptophysin complex. The highlighted area represents the lipid bilayer. The
transmembrane segments of the MARVEL domai are indicated.
MAL shares significant sequence similarity in its four transmembrane domains with
other integral membrane proteins. This allows the definition of a domain, called the MAR-
VEL (MAL and related proteins for vesicle formation and membrane link) domain, that is
present in 24 human proteins. These constitute the MARVEL superfamily and are conserved
across species [8]. The MARVEL superfamily includes the CMTM (chemokine-like factor
MARVEL transmembrane domain containing) [9], MAL [10,11], physin [12,13], and TAMP
(tight junction-associated MARVEL) [14] families (Figure 1B). The MAL family consists of
seven members. MAL2, MALL/BENE, PLLP and CMTM8 display a tetraspanning topol-
ogy similar to that of MAL. The other two members, myeloid differentiation-associated
marker (MYADM) and MYADM-like2 (MYADML2), contain an additional MARVEL do-
main and form an independent branch within the family. Synaptophysin, which is the
most abundant protein in synaptic vesicles [15], is the only MARVEL superfamily member
whose 3D structure has been determined so far [16]. Synaptophysin adopts a hexameric
basket-like complex with six spokes each, corresponding to a synaptophysin subunit, with
an extended, open conformation on the vesicle lumen and a closed end containing the N-
and C-termini on the cytosolic side of the vesicle membrane (Figure 1C). This structure
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is consistent with the proposed role of synaptophysin as a component of the fusion pore
during synaptic vesicle exocytosis [17,18]. It is currently unknown whether MAL or other
members of the MARVEL superfamily have a similar hexameric structure.
In this review, we address the biochemical properties and expression pattern of the
MAL protein, its function in specialized routes of membrane trafficking in T cells, epithelial
cells and myelin-forming cells, and its role in the organization of specialized membranes.
The role of MAL as a receptor for the Clostridial epsilon toxin, the epigenetic regulation
of MAL gene expression in cancer, and the use of MAL as a cancer biomarker are also
discussed.
2. Tissue Specific Expression, Intracellular Distribution, and Biochemical Properties
of MAL
2.1. MAL Expression Is Restricted to Specific Tissues and Cell Types
The generation of a highly specific anti-MAL antibody mouse mAb 6D9 allowed MAL
expression and distribution to be immunohistochemically analyzed in frozen or paraffin-
embedded human tissue (Table 1) [19,20]. The analysis revealed that MAL is strongly
expressed in the epithelial cells of distal, but not proximal, tubules and collecting ducts of
the kidney, and in many types of polarized epithelial cells, such as those lining the follicle
lumen in the thyroid or the prostate acini. MAL is also expressed in: the stratified squamous
epithelium of the esophagus; crypt cells and brush border enterocytes in the gut; type 2, but
not type 1, pneumocytes in the lung; and in the transitional epithelium of the urothelium,
most prominently in the superficial layer. The thymus cortex, paracortical T lymphocytes
of lymph nodes, and peripheral blood T lymphocytes, as well as myelin-forming cells in
peripheral nerve endings are also positive for MAL expression. Sporadic cells in the thymus
medulla and in the lymph node follicles also express MAL [19,20]. In contrast to the lack
of MAL expression in endothelial cells, high endothelial venules endothelium is positive,
with a characteristic apical distribution. This differential expression was confirmed by
DNA microarray analysis [21]. MAL expression was undetectable in fibroblasts, muscle
cells and endothelial cells. The expression of MAL in myelin in the peripheral and central
nervous system was confirmed in rats and mice [22,23]. In addition, although it has not
been as extensively studied in mice as it has in humans, the tissue distribution of MAL
appears concordant in the two species except that, in mice, peripheral blood lymphocytes
and their thymic precursors do not express MAL [23,24].
Table 1. Distribution of MAL in some human tissues.
Tissue/Organ Cells Positive for MAL Expression
Esophagus Stratified squamous epithelium
Stomach Surface mucus cells, parietal cells, chief cells
Small intestine Enterocytes, crypt cells, Paneth cells
Large intestine Mucus cells
Pancreas Acinar cells, ductal cells, endocrine cells
Kidney Distal convoluted tubules, collecting tubules, loop of Henle
Bladder/ureter Superficial cells from transitional epithelium
Prostate Ductal and acinar cells
Thymus Cortical thymocytes, medullary thymocytes, Hassall’s corpuscles
Lymph node T cells, high endothelial cells venules endothelium
Bronchi/trachea Respiratory epithelium, goblet cells
Lung Type 2, pneumocytes, mucus cells
Thyroid Thyrocytes
Testis Leidy cells, Sertoli cells
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In conclusion, MAL is characterized by an expression pattern restricted to specific cell
types and tissues.
2.2. MAL Is Mainly Found at the Plasma Membrane and Cytoplasmic Tubulovesicular Structures
A quantitative electron microscopy analysis of MDCK cells stably expressing c-myc-
tagged MAL [25] indicated the presence of MAL at the plasma membrane (12% of the
total label), including clathrin-coated pits and buds, and cytoplasmic structures (88% of
the total label). Most of the cytoplasmic labeling occurred in uncoated tubular/vesicular
structures (82% of the total), with smaller fractions in clathrin-coated structures (4% of the
total), multivesicular endosomes (MVE; 1.4% of the total), and Golgi-associated structures
(0.6% of the total). This subcellular distribution suggests that MAL might move between
distinct compartments. This possibility was confirmed by tracking the movement of the
subpool present in the plasma membrane, which revealed continuous shuttling of MAL
between the plasma membrane and the Golgi [26].
2.3. MAL Has Unusual Biochemical Properties
2.3.1. MAL Is a Proteolipid Protein
The term proteolipid was originally coined to designate a complex protein fraction
present in brain myelin extracts that partitioned with myelin lipids in organic solvents, such
as chloroform:methanol mixtures, which are commonly used to extract cell lipids [27]. Pro-
teolipids later came to be operationally defined as membrane proteins from any source that
display unusual lipid-like properties that make them partition into lipophilic solvents [28].
The proteolipid group includes proteins with very different structures and functions, in-
cluding the proteolipid protein (PLP), which is a major component of myelin membranes,
and the 16-kDa subunit of the Vo sector of the eukaryotic H+-pump V-ATPase [28]. The
MAL protein, which displays a hydrophobicity profile quite similar to that of the 16-kDa
Vo proteolipid, partitions selectively into the organic phase when cells are extracted with
lipophilic solvents [29]. This unusual biochemical feature qualifies MAL for inclusion in
the proteolipid group.
2.3.2. MAL Selectively Partitions into Condensed Membranes
Studies in model membranes have shown that collective interactions between sterols
and saturated lipids induce the formation of condensed yet fluid “liquid-ordered” (Lo)
phases coexisting with “liquid disordered” (Ld) phases [30–32]. Membrane nanodomains—
often referred to as “liquid ordered” (Lo)-like membranes, condensed membranes or
rafts—are specialized cellular membrane subdomains whose physicochemical properties
include dense lipid lateral packing, enrichment in sterols and saturated acyl chains, and a
transient lifetime [33,34].
The tight packing of lipids in condensed membranes confers resistance to solubiliza-
tion by nonionic detergents, such as Triton X-100, at low temperature [35,36]. Although
the association of proteins with detergent-resistant membranes (DRMs) does not neces-
sarily mean that the partitioning of those proteins in condensed membranes precedes
experimental manipulation, since it can also arise as an artifact of the detergent extraction
procedure [37], DRMs are enriched in proteins associated with condensed membrane
subdomains in the cell. A short peptide motif (Leu-Ile-Arg-Trp, LIRW) situated close
to the C-terminus and that is located at a cytoplasmic interface of the protein with the
lipid bilayer is essential for partitioning MAL into DRMs [38]. Pulse-chase experiments
indicated that whereas a MAL protein with an ILRW sequence fractionated into DRMs
soon after biosynthesis, a similar protein ending with an ILKW sequence was found in
the soluble fraction due to a trafficking defect that impedes the export of MAL from the
ER [39]. These results argue against the possibility that the acquisition of insolubility by
MAL is an artifact of the DRM isolation procedure, and suggests that intact MAL resides in
compact membranes in the cell, even though MAL is compatible with both insoluble and
soluble membranes. This dual compatibility is also supported by in vitro reconstitution
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experiments in artificial membranes [40]. In conclusion, the selective association of MAL
with DRMs in all the cell types assayed appears to be a genuine feature related to its
capacity to interact with a compact lipid environment.
The high affinity of MAL for condensed membranes was confirmed in an in vitro
system based on cell-derived giant plasma membrane vesicles, which separate into coexist-
ing ordered and disordered lipid phases. In this system, MAL partitions into condensed
domains in giant plasma membrane vesicles with an affinity greater than that of all the
other transmembrane proteins analyzed and similar to that of prototypical raft markers,
such as glycosylphosphatidylinositol (GPI)-anchored proteins and cholera toxin, which
binds the GM1 ganglioside [41].
Membrane condensation can be measured in live cells using polarity sensitive dyes,
such as laurdan (6-lauryl-2-dimethylamino-napthalene) [42,43]. These membrane probes
do not preferentially partition into a particular type of membrane, but their fluorescence
emission spectrum undergoes a red shift depending on the degree of condensation of
the membrane environment in which they are inserted, making it possible to distinguish
densely packed, ordered membranes from those with a loosely packed, disordered structure.
Consistent with its selective partitioning into DRMs, the use of laurdan indicates that MAL
selectively distributes in compact membranes in epithelial cells and T lymphocytes [44–46].
In summary, MAL displays unique features that impart selective preference for con-
densed membranes both in vitro and in live cells. Henceforth, we will use association with
DRMs to refer to the partition of a molecule into the insoluble membrane fraction isolated
by biochemical means, whereas distribution in condensed membranes will refer to the
presence of a molecule in highly ordered membrane domains of the cell.
3. The Role of MAL in Epithelial Cells
Polarized epithelial cells transport newly synthesized proteins to the apical surface
directly from the Golgi or through an indirect route, which consists of endocytosis of
cargo at the basolateral surface and its posterior traffic in vesicular carriers across the cell,
in a process known as transcytosis [47,48]. The observations that the apical membrane
of epithelial cells is enriched in glycolipids relative to the basolateral surface and that
the sorting of glycolipids and proteins takes place at the trans-Golgi network constitute
the basis of the proposal of raft-mediated transport to the apical surface [49,50]. This
hypothesis was supported by experimental evidence showing that artificial membranes
consisting of glycolipids and cholesterol are insoluble in non-anionic detergents such
as Triton X-100 [50,51], and by the observation that membrane proteins relying on the
direct route, such as the influenza virus hemagglutinin (HA) and GPI-anchored proteins,
become resistant to detergent solubilization during biosynthetic transport to the apical
membrane [52,53]. In accordance with the original formulation of the raft-mediated model
of apical transport [54], the association of glycosphingolipids with cholesterol generates
raft platforms at the trans-Golgi network that are immiscible in the other phospholipid-
enriched membranes. These platforms recruit specific proteins that are then transported in
vesicular carriers made of raft lipids.
3.1. MAL in Apical Transport in Cultured Cells
In the original proposal of rafts as platforms for apical transport, the existence of a
specialized protein machinery was postulated to make the rafts competent for transport.
This machinery would consist of a minimal set of proteins to ensure the processes of
vesicle formation, cargo recruiting, targeting and fusion to the apical surface [54]. One
approach used to identify this machinery involved the sequencing of proteins present
in detergent-resistant membrane fractions from total cellular membranes after protein
separation by two-dimensional gel electrophoresis. Caveolin [55], VIP36 [56], annexin
XIIIb [57], and MAL [4] were identified by this approach, and were proposed as candidates
to be components of the apical transport machinery. Subsequently, it was shown that ex-
ogenous (HA and p75NTR) and endogenous (gp114) single-span transmembrane proteins,
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chimeric GPI-anchored proteins (YFP-GPI and gD1-DAF), and exogenous (thyroglobulin)
and endogenous (gp80/clusterin) secretory proteins [58–61] require MAL expression to be
transported to the apical surface of MDCK cells in an efficient manner. It is of note that one
set of studies emphasizes that the kinetics of apical delivery of newly synthesized proteins,
but not the targeting of apical proteins, was affected by MAL depletion, as they were found
in the apical surface at steady state [59–61]. Another study, however, claimed that apical
targeting was impaired, as the apical markers assayed concentrated at the Golgi and were
nearly absent from the apical surface at steady state [58]. Whether these differences were
due to the different systems used to knock down (KD) MAL expression—antisense oligonu-
cleotides in the first case, and inducible expression of antisense RNA in the other—and/or
the extent of MAL silencing has not been addressed. The slow kinetics of apical delivery
observed in MDCK cells with depleted levels of MAL was recapitulated in epithelial Fisher
rat thyroid cells [60], confirming the requirement of MAL for efficient apical transport by
the direct route.
Unlike simple epithelial cells that directly transport GPI-anchored and single trans-
membrane domain proteins from the trans-Golgi network to the apical surface, in hepato-
cytes these proteins reached the apical membrane by basolateral-to-apical transcytosis [62].
Consistent with the absence of a direct route, MAL is not expressed in hepatocytes and
hepatic cell lines such as HepG2 and WIF-B cells [63,64]. It is of note that GPI-anchored
proteins and apical single transmembrane proteins do not partition into DRMs in control
WIF-B cells but do so in WIF-B cells expressing MAL exogenously, and MAL reroutes them
into the direct pathway [64]. These findings support the role of MAL as a component of the
machinery of the direct route of apical transport mediated by raft membranes (Figure 2A).
3.2. MAL in Apical Transport: KO Mice
The apical surface of mammalian bladder epithelium contains one of the most ef-
fective permeability barriers known to exist in nature, whose function is to protect the
epithelium from the urinary components. To accomplish this, the most superficial layer of
urothelial cells is almost completely covered by large (0.10–1 µm) two-dimensional crystals
of 16-nm uroplakin particles [65], known as urothelial plaques, comprising four major
integral membrane proteins called uroplakins: tetraspanins Ia and Ib, and the single-span
membrane proteins II and IIIa [66]. The intracellular trafficking of these plaques to the
apical membrane is mediated by fusiform vesicles (500–800 nm), which consist of two
plaques connected by a flexible, detergent-insoluble hinge region [67,68].
MAL expression is associated with in vitro urothelial cell differentiation [69]. Con-
sistent with this finding, MAL is expressed in human [19] and mouse urothelium [70], as
revealed by immunohistochemical analysis. As in other epithelial cells, MAL and uro-
plakins fractionate into DRMs of urothelial cells. In the superficial layer, MAL is present
at the plasma membrane between adjacent plaques, and in the fusiform vesicles exclu-
sively occupies the hinge region, which is the zone involved in fusion with the plasma
membrane [70]. Consistent with the role of MAL in apical transport in MDCK cells, MAL
knockdown (KD) decreases the rate of delivery, but not the targeting, of exogenous uro-
plakins to the apical membrane of MDCK cells. It is of note that urothelial cells from MAL
knockout (KO) mice accumulate a large number of fusiform vesicles at their apical aspect,
although the surface content of urothelial plaques is normal at steady state, indicating that
the delivery but not the targeting of uroplakins is affected. In uroplakin-II KO mice, the
formation of fusiform vesicles is blocked and, instead, vesicles of smaller size (~200 nm)
appear that are positive for MAL but lack uroplakin plaques [70]. These findings suggest
that, although MAL and uroplakins are able to form distinct types of vesicles in the absence
of the other, they only form fusiform vesicles that are completely functional in plaque
delivery when they are expressed together. The fact that MAL is present not only in the
hinge areas of the fusiform vesicles but also in the hinge areas of the apical surface suggests
that MAL might play a role in the fusion event leading to plaque delivery. This role would
be consistent with the presence in MAL of a MARVEL domain, which, in synaptophysin,
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has been suggested to form part of a fusion pore complex that regulates synaptic vesicle
exocytosis [17,18].
Similar to MAL, the v-SNARE protein VAMP8/endobrevin localizes at the hinge
zone of fusiform vesicles [71]. Unlike MAL KO mice, which have a normal content of
urothelial plaques at their apical surface, superficial urothelial cells from VAMP8 KO mice
lack surface urothelial plaques but, as in MAL KO mice, form morphologically normal
fusiform vesicles that do not fuse with the apical membrane [71]. Therefore, MAL appears
to facilitate SNARE-mediated fusion of fusiform vesicles with the apical surface for efficient
urothelial plaque delivery (Figure 2A).
3.3. MAL in Apical Endocytosis
Since MAL continuously internalizes from the apical membrane [26], it was of interest
know whether its internalization is used for the endocytosis of apical proteins. Consistent
with this possibility, MAL and apical polymeric immunoglobulin receptor were visual-
ized in the same endocytic vesicles by videomicroscopy, and were identified in the same
clathrin-coated pits and vesicles by electron microscopy. Moreover, MAL silencing experi-
ments indicated that apical, but not basolateral, endocytosis of the receptor requires MAL
and clathrin. In contrast, the GPI-anchored folate receptor internalizes from the apical
membrane in a MAL and clathrin-independent manner [72]. Therefore, in addition to
controlling the traffic of proteins from the Golgi to the apical surface, MAL regulates a
specialized pathway of endocytosis from the apical surface (Figure 2A).
3.4. MAL in Apical Retention of Membrane Proteins
In the human kidney, MAL is expressed in distal tubules, Henle’s loop and collecting
ducts, but not in proximal tubules and glomeruli [19]. The aquaporin-2 (AQP2) water
channel is expressed exclusively in epithelial cells of the renal collecting duct [73]. AQP2
regulates water reabsorption by redistributing itself between intracellular vesicles and
the apical cell surface in a process controlled by the antidiuretic hormone arginine va-
sopressin [74]. The renal-specific Na+-K+-2Cl− cotransporter (NKCC2) is expressed in
epithelial cells of the ascending limb of Henle’s loop. NKCC2 is responsible for Na+ and
Cl− reabsorption and the maintenance of normal blood pressure. Consistent with the
absence of MAL in proximal tubules [19], LLC-PK1 cells, which derive from this type of
structure, do not express MAL endogenously [75]. Ectopically expressed tagged MAL in
LLC-PK1 associates with AQP2 and NKCC2 and causes their retention at the apical surface
by decreasing their internalization. This observation was interpreted as indicating that
MAL has a role in the apical retention of membrane proteins (Figure 2A) [75,76]. However,
the overexpression of MAL, the presence of a tag in MAL, and the use of a cell line that does
not express endogenous MAL limit the validity of this conclusion. Further work in renal
epithelial cells positive for endogenous MAL expression, the analysis of the effect of MAL
silencing, and the use of exogenous MAL expression in rescue-of-function experiments are
needed to provide more compelling evidence that MAL plays such a role.
3.5. MAL in Apical Lumen Formation
The formation of an apical lumen is a key step during epithelial tissue morphogene-
sis [77,78]. Lumen-containing organs are spherical, as in the case of the thyroid follicles,
or tubular, as in the case of the branched tubules of mammary glands or lungs or the
unbranched ones of the sweat glands. Defects in lumen formation are associated with a
variety of disorders such as polycystic kidney disease and vascular stenosis, which are
characterized by abnormal dilation of renal tubules or a reduction in the lumen size of
blood vessels, respectively [79].
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cells conjugated with an antigen-presenting cell in the presence of antigen, MAL transports Lck to the immunological
synapse. (C) In oligodendrocytes, MAL is important for proper architecture of nodes of Ranvier (boxed). Compared with
wild-type mice, MAL KO mice show paranodal loops detached from the axon and reduced content of neurofascin (NF155),
myelin-associated glycoprotein (MAG) and myelin basic protein (MBP) in myelin. (D) In T cells, and also probably in
epithelial cells, MAL is important for generating intraluminal vesicles that will be secreted to the extracellular milieu as
exosomes after fusion of the MVEs with the plasma membrane. In the absence of MAL expression, the release of exosome
particles and markers is greatly reduced.
Mice overexpressing MAL develop multiple large renal cysts, with a close correlation
between MAL expression levels and cyst development, the affected tubular segments
expressing the highest levels of MAL. Detailed analyses revealed that the cysts probably
developed from the distal convoluted and connecting tubuli, whereas proximal convoluted
tubuli appeared to be undamaged [80]. MDCK cells have been widely used as a cell
model system to study the process of single lumen formation [47,81]. When these cells
are cultured in a three-dimensional matrix such as Matrigel®, they form spheres that
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progressively mature to form hollow structures, referred to as cysts. These consist of a
single layer of epithelial cells with their apical surfaces lining an inner single lumen, and
their basolateral surface contacting the extracellular matrix. Defects during this process
lead to the formation of multiple lumens of smaller size [79]. Oligonucleotides designed to
knock down MAL expression [82], as well as tagged-MAL overexpression [83], produce
cysts with multiple lumens in MDCK cells. Since MAL overexpression produces dilated
apical surfaces in MDCK cells [58], it is plausible that that the effect of MAL overexpression
on the formation of multiple lumens in MDCK cells or of renal cysts in mice arises from
the production of a large excess of apical membrane. However, it remains unclear how
MAL silencing produces the same effect. In conclusion, although the exact role of MAL in
the process is still unknown, fine-tuning MAL levels appears to be important for normal
cystogenesis in renal cells.
3.6. MAL and Primary Cilium Biogenesis
The primary cilium is a single appendage that protrudes from the cell surface of
most mammalian cells. It is made up of a ciliary membrane that surrounds a microtubule-
based scaffold, known as the axoneme, that is derived from the older centriole in the
centrosome [84]. Primary cilia recognize a wide range of environmental signals and
transmit them to the cell body [85]. Defects in primary cilium functioning are associated
with a long list of developmental and degenerative disorders [86,87].
In MDCK cells, MAL accumulates predominantly at the base of the cilium in mod-
erately confluent cultures and also at the primary cilium at high cell density [46]. MAL
KD results in a drastic drop in the percentage of ciliated cells [46,82]. The components
of the machinery for ciliary growth are recruited normally to the centrosome zone under
those conditions but are unable to elongate the primary cilium correctly and, consequently,
the remaining cilia are stunted [46]. This effect of MAL silencing seems to be due to defi-
cient condensation of the centrosome-associated membranes needed to build the ciliary
membrane [88,89]. The overexpression of tagged MAL in MDCK cells and in transgenic
mice also gives rise to fewer, shortened cilia. This may have been caused by excessive
condensation of the ciliary membrane precursor associated with the centrosome, although
this effect was not investigated at the time. In summary, MAL levels modulate proper
primary cilium formation and elongation in renal cells (Figure 2A).
4. MAL in T Lymphocytes
4.1. MAL Expression in T Lymphocytes
Flow cytometry analysis with anti-MAL mAb 6D9 indicates that MAL is strongly
expressed in thymocytes, in a large percentage (65–90%) of peripheral CD4 T cells, and
in a lower proportion (31%) of CD8 peripheral T cells. Consistent with the absence of
MAL expression in B cell lines [1], CD19+ B cells were negative. MAL is not significantly
expressed in peripheral blood B cells or in B cell subsets of tonsil and spleen [20].
Engagement of the T cell receptor (TCR) triggers a program of activation of gene
expression. Costimulatory molecules provide additional signals that amplify those of
the TCR and determine T cell fate. As a result, T cells undergo anergy, apoptosis, clonal
expansion, or differentiate into helper T (Th) or regulatory T cells (Treg) cells [90]. CD28
and inducible costimulatory (ICOS)/CD278 are two costimulatory molecules of the same
family that have distinct in vivo functions [91]. In a study to compare the programs of gene
activation elicited by CD28 and ICOS costimulation, MAL was found among the small
number of genes whose level of activation was higher in the case of ICOS costimulation,
suggesting that MAL gene expression is regulated in different ways by CD28 and ICOS [92].
Depending on how IL-2 and interferon-α and IL-4, IL-5 and IL-13 are expressed, Th cells
are subdivided into Th1 and Th2, respectively [93]. Atopic diseases, such as asthma, atopic
dermatitis and rhinoconjunctivitis, are associated with Th2-driven inflammatory responses
to common allergens. MAL was one of the genes found to be upregulated in the T cells of
atopic disease patients compared with controls [94–96]. A subsequent study indicated that
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IL-4 expression is necessary to activate MAL gene transcription, prompting the authors to
hypothesize that MAL might be involved in Th2 differentiation [96].
4.2. MAL on Vesicular Traffic of the Tyrosine Kinase Lck
Endogenous and exogenous MAL selectively partitions into DRMs from human T
cell lines and peripheral blood T cells [97,98]. MAL was found to be >104-fold enriched
in DRMs from the human HPB-ALL T cell line, similar to CD55, which is associated
with the exoplasmic leaflet of the plasma membrane by a GPI-anchor. Its level is higher
than that of the non-receptor Lck tyrosine kinase (~400-fold), which is associated with
the inner leaflet through myristic and palmitic acid chains that are covalently attached
to its N-terminal end. MAL cofractionates with Lck in the DRM fraction obtained from
endosomal membranes, and both proteins colocalize in endosomal structures in Jurkat T
cells and human peripheral blood T lymphocytes [98]. MAL and Lck travel in the same
transport vesicles following microtubule tracks leading towards the plasma membrane [45].
The movement of these vesicles requires the MAL-associated formin INF2 [99]. In the
absence of MAL, Lck accumulates in internal membranes and does not reach the plasma
membrane efficiently. As a consequence, TCR-mediated cell signaling, which is known
to require plasma membrane-associated Lck, is impaired, which is an indication of the
importance of the role of MAL in human T cells [24]. In a recent study based on the use of
a new mAb (MT3) that was generated to CD3-coprecipitated complexes, and that stains
the T-cell surface only when MAL is expressed, it was suggested that MAL is involved in T
cell differentiation but not in Lck transport [100]. However, since biochemical evidence
showing that mAb MT3 recognizes MAL is lacking, it cannot be ruled out that mAb MT3
recognizes a protein whose transport to the cell surface is dependent on MAL, expression
or an epitope associated with the TCR/CD3 complex that is unmasked only in the presence
of MAL. It is of particular note that HIV-1 Nef specifically hijacks the MAL-mediated
route of Lck transport by associating with MAL and the small GTPase Rab11b, leading
to intracellular accumulation of Lck [101]. In conclusion, MAL has a crucial role as a
component of the Lck transport machinery in T cells [102].
4.3. Subcompartmentalization of the Immunological Synapse
T lymphocytes polarize when they recognize an antigen presented by an antigen-
presenting cell, forming a specialized domain, known as the immunological synapse (IS),
at the zone of membrane contact between the two cells, and reorient the centrosome to face
the IS. The IS consists of a supramolecular activation complex (SMAC) that is organized
into two concentric membrane subdomains: a central complex (cSMAC) made up of the
TCR, Lck and the transmembrane LAT adapter, and a peripheral ring (pSMAC), comprising
cytoskeletal components and adhesion molecules [103]. In the absence of MAL, T cells form
an IS but the neither the TCR nor Lck are targeted to the cSMAC and the centrosome does
not reorient [24], suggesting that MAL has an important role in IS assembly (Figure 2B).
Further evidence of the role of MAL in the correct assembly of the IS comes from the
finding that the expression of a MAL molecule artificially targeted to the pSMAC missorts
Lck and LAT to the pSMAC, and redistributes the docking machinery for transport vesicles
and microtubules and transport vesicles from the cSMAC to the pSMAC [45]. Once MAL
has delivered Lck to the IS, synaptic Lck, in turn, regulates the fusion of LAT- and TCR-
containing transport vesicles to the IS to complete the assembly of the IS, thereby enabling
TCR-mediated signaling [24,104]. Therefore, MAL is at the top of a hierarchically organized
set of membrane trafficking pathways that delivers Lck to the IS and that enables the
sorting and transport of other relevant components to the cSMAC.
5. MAL in Myelin-Forming Cells
5.1. The Role of MAL in Myelin Proteolipid Protein (PLP) Targeting to Myelin in Cultured Cells
Oligodendrocytes and Schwann cells produce vast amounts of myelin, a multilamellar
membrane that wraps the axons of the central and peripheral nervous system (CNS and
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PNS), respectively. The myelin sheath is continuous with the plasma membrane and forms
specialized subdomains with distinct lipid and protein composition that are generated and
maintained by specialized processes of membrane trafficking [105,106]. MAL expression
in oligodendrocytes was identified by differential screening of an oligodendrocyte cDNA
library [3], and by the sequencing of proteins present in the DRM fraction of oligodendro-
cytes [2]. In situ hybridization techniques indicated that MAL is expressed not only in
oligodendrocytes but also in Schwann cells [3]. Consistent with this finding, immunohisto-
chemical [3,22,107], cell fractionation [108], and immunoblot analyses indicate the presence
of MAL in myelin from both the central and peripheral nervous systems [3,23,108].
MAL is expressed in the CNS of rats during the late stages of myelination, whereas
it is detected prior to the onset of myelination in the PNS. This observation led to the
suggestion that MAL plays different roles in oligodendrocytes and Schwann cells. Thus,
the late expression of MAL protein in the CNS is consistent with a role for it in the final
stages of myelin sheath formation, such as the stabilization of the compacted myelin
membranes, whereas the early expression of MAL protein in the PNS suggests that MAL
is involved in Schwann cell differentiation and the onset of myelination [22]. In situ
hybridization revealed that MAL is expressed in the human CNS and especially in the grey
matter of the cerebral cortex, with less in the cerebellum and the amygdala and little or
none in the subcortical white matter [109]. NTERA2 cells, which were isolated from the
TERA2 teratocarcinoma-derived cell line, differentiate into neurons and other cell types
when exposed to retinoic acid. Further evidence of the expression of MAL in neurons in
the CNS comes from the finding that treating NTERA2 cells with retinoic acid induces
MAL expression [109]. Comparative immunohistochemical analysis of human and rat
brain needs to be performed to establish whether there is species-specific expression of
MAL in CNS neurons.
Primary oligodendrocytes in monoculture express myelin components and form
highly branched myelin-containing structures, called myelin sheets [110]. HA [111] and the
major myelin-specific proteolipid PLP fractionate into DRMs in these cells and appear to
use a pathway reminiscent of the sphingolipid-mediated route of apical transport to the cell
body plasma membrane [111,112]. PLP, but not HA, is then transported by transcytosis to
myelin sheets, in a process probably mediated by the MAL family member MAL2 [63,113],
after having undergone a conformational change triggered by sulfatide that forces PLP to
switch from being Triton X-100-insoluble to a Triton X100-soluble and CHAPS-insoluble
form [114]. MAL overexpression does not affect the initial transport of PLP to the cell body
plasma membrane but interferes with the conformational change required for the transcy-
totic transport of PLP to the myelin sheets. This facilitates lateral diffusion of PLP directly
from the plasma membrane to the myelin membrane [112]. Therefore, MAL appears to
switch the mode by which PLP reaches the myelin sheath from one of transcytosis, when
MAL is not yet expressed, to one of lateral diffusion, during the late stages of myelinization
when MAL is expressed. Since sulfatide triggers the conformational change of PLP, and
MAL is associated with sulfatide [107], it is plausible that MAL mediates this switch by
associating with sulfatide and impeding the conversion of PLP to the Triton X-100-soluble
and CHAPS-insoluble form. The switch in the mechanism of PLP access into myelin
might be important during development, since MAL expression takes place when myelin
compaction has already started to make vesicular trafficking difficult [112]. Septins, which
are guanine nucleotide-binding proteins that form high-order polymers [115], interact with
MAL, and this interaction could be involved in structuring the myelin membrane [116].
Metachromatic leukodystrophy is a lysosomal lipid storage disease caused by aryl-
sulfatase A deficiency, which leads to sulfatide accumulation and thereby progressive
demyelination [117]. In arylsulfatase A-deficient mice, a mouse model of the disease,
the accumulation of sulfatide occurs not only at lysosomes but also in myelin itself. It
causes a dramatic reduction in MAL levels, but does not affect the overall composition
of myelin [118]. This effect, together with the observation that sulfatide accumulation
diverts MAL to the late endosomal/lysosomal compartment, reinforces the link between
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sulfatide and MAL and suggests that deficient MAL levels and/or MAL mistargeting may
contribute to the pathogenic mechanism of metachromatic leukodystrophy.
5.2. MAL in Myelin-Forming Cells in Mice
The role of the MAL protein in myelin-forming cells has also been studied in mice that
overexpress or lack MAL expression [80,119,120]. Transgenic mice that express an excess
of MAL exhibit delayed onset of myelination and progressive segregation of unmyelinated
axons in the PNS, and hypomyelination and aberrant myelin formation in the CNS, which
is evidence of MAL’s role in myelin formation [80]. The expression of the p75 neurotrophin
receptor gene, which mediates the axon–glia interaction during ensheathment and myelin
wrapping, is reduced in peripheral nerves of mice that overexpressed MAL [120]. Com-
pared with wild-type mice, shorter intermodal length was observed in the peripheral
nerves of MAL overexpressing mice, while it was longer in MAL KO mice [120]. This
finding indicates that MAL expression affects the longitudinal extension of the myelin
sheath. MAL overexpression alters the expression of a number of genes that influence the
cytoskeletal organization and differentiation of Schwann cells [121], helping to explain
the effect observed in PNS myelination. In the CNS, the organization of Ranvier nodes is
defective in MAL KO mice, mainly in the paranodal zone [119], which is the zone where
myelin anchors to the axon [122]. The incorporation of the paranodal protein neurofascin
55 and other myelin proteins is reduced (Figure 2C), explaining the anomalies observed
in myelin organization [119]. In conclusion, in the CNS, MAL plays an important role in
axon–glia interaction in the adult whereas MAL influences the expression of components
that mediate this interaction during ensheathment and myelin wrapping in the PNS.
6. Role of MAL in Exosome Secretion
Exosomes are extracellular vesicles, 50–100 nm in length, that arise from the discharge
of preformed intraluminal vesicles within MVEs to the cell exterior by fusion with the
plasma membrane [123]. Exosomes play an active role as vehicles for transporting a wide
range of bioactive molecules (receptors, enzymes, cytokines, mRNA, miRNA, etc.) between
different cells and tissues to modulate their activity. This important function represents a
general mechanism of intercellular communication that controls development and a wide
range of normal and pathological processes [124].
6.1. MAL in Prostasomes
Prostasomes are specialized exosomes secreted by the prostate gland involved in
the immune protection of sperm cells and promotion of the fertilizing ability of sperm
cells [125]. MAL localizes to multivesicular endosomes that contain other MAL family
proteins, GPI-anchored proteins and caveolin-1, and is found in prostasomes secreted by
prostate cancer PC-3 cells [126]. Since prostasomes are highly enriched in raft lipids [127],
it is plausible that MAL participates in prostasome biogenesis. However, the direct involve-
ment of MAL in this process has not yet been addressed.
6.2. MAL in Exosome Biogenesis by T Lymphocytes
Videomicroscopic analysis of Jurkat T cells revealed the presence of MAL in large
endosome structures that were also positive for the tetraspanin protein CD63, a prototypical
marker of exosomes [128]. Some of these endosomes were found to move towards the
plasma membrane and discharge their content into the extracellular space. Evidence of the
involvement of MAL in exosome biogenesis came from the reduced number of exosomes
secreted in MAL KD cells, as assessed by the direct visualization of exosome particles
by electron microscopy, and the decreased content of exosome cargo, as demonstrated
biochemically. The effect of MAL KD on exosome production is correlated with reduced
sorting of CD63 into the intraluminal space of MVEs and with the accumulation of CD63
on the limiting membrane of aberrant MVEs that no longer fuse with the plasma membrane
but, instead, merge with autophagic vacuoles and lysosomes [128]. Ceramide is important
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for the formation of intraluminal vesicle destined for exosomes in T cells, given that the
silencing of neutral sphingomyelinase II or inhibition of its enzymatic activity impairs
exosome release [129]. Since the effects of the inhibition of ceramide synthesis and of
MAL depletion are similar, it was proposed that MAL organizes ceramide patches at the
MVE-limiting membrane to promote cargo selection, and the inward invagination of the
patches leading to the formation of intraluminal vesicles destined for exosome secretion
(Figure 2D) [130].
Expression of the HIV-1 accessory protein Nef induces massive secretion of exosome
markers in T cells [129]. Consistent with the involvement of MAL in exosome secretion in
T cells, the release of the exosome markers was resilient to Nef expression in MAL KD T
cells [128]. This finding supports the role of MAL as a critical component of the machinery
for exosome biogenesis by human T cells.
7. MAL in Other Cell Systems and Processes
Interleukin (IL)-11, which is a member of the IL-6 family, exhibits pleiotropic functions,
including hematopoiesis, bone development, tissue repair, and tumor development [131].
Human umbilical cord blood mononuclear cells are a rich source of stem and progenitor
cells that could be of interest in repairing perinatal brain damage [132], and acute myocar-
dial infarction treatment [133]. IL-11 induces MAL expression in human umbilical cord
blood mononuclear cells [134], consistent with MAL playing a role in tissue repairing by
these cells.
Membrane-type 1 matrix metalloproteinase (MMP1) promotes cell migration and
invasion and is involved in cancer cell invasion, metastasis and growth, angiogenesis,
epithelial morphogenesis, skeletal development, inflammation, atherosclerosis, obesity,
and rheumatoid arthritis [135]. MMP1 associates with MAL in co-immunoprecipitation
experiments in COS cells that overexpress the two proteins. It is interesting to note that
MAL expression reduces the invasion and migration capacity of MMP1-transfected cells,
suggesting that MAL might regulate MMP1 activity [136]. Although it is of interest, the
physiological role of this interaction is not known.
Maternal viral infections are recognized to have detrimental effects on the human fetus
and serious consequences for the development and viability. A link has been established
between maternal influenza infections and pre-term birth, low birth weight, congenital
defects of the heart, cardiovascular disease as adults, and neurological and behavioral
abnormalities [137]. In mice, influenza virus infection impairs the development of the
fetal immune system and causes the downregulation of the expression of the MAL gene in
developing fetal thymus [138]. However, since MAL is expressed neither in adult thymus
nor peripheral T cells in mice [45], it is not clear that this effect is related to the observed
defects in immune system development.
In HOG oligodendroglioma cells, herpes simplex virus type 1 particles colocalize
partially with exogenous MAL [139]. Moreover, MAL depletion reduces the cell-to-cell
spread of herpes simplex virus 1. This finding prompted the authors to suggest that MAL is
necessary for the efficient spread of the virus [140]. However, as endogenous expression of
MAL in HOG cells was not demonstrated and, consequently, the silencing of endogenous
MAL could not be directly assessed, this hypothesis awaits confirmation.
8. MAL and the Clostridial Epsilon Toxin
Clostridium perfringens types B and D produce epsilon-toxin (ETX), which is a potent
pore-forming toxin that is responsible for devastating enterotoxemia in ruminants, which
causes important economic losses. The toxin is produced in the gut of these animals and
crosses the gut wall to enter the bloodstream, where it binds with great specificity to a
restricted number of organs and structures, such as kidney, lung, blood–brain barrier
endothelial cells and myelin. It causes perivascular edema in various tissues, accumulates
in the kidney, and produces blood–brain barrier dysfunction and white matter injury [141].
ETX has been proposed as a possible environmental trigger for multiple sclerosis [142], a
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human inflammatory disease in which the blood–brain barrier is disrupted and myelin-
forming cells of the CNS are injured [143,144], in a similar way to the alterations occurring
during ETX-produced enterotoxemia in livestock.
ETX oligomerizes and forms channels in sensitive cell lines such as MDCK [145,146].
In these cells, ETX binds to condensed domains of the plasma membrane [147], is recovered
in DRMs after binding to the cell surface [148], and binds to DRMs and to lipids extracted
from them [149]. In overlays assays, ETX binds to sulfatide and phosphatidylserine [149].
Sulfatide is necessary for ETX cytotoxicity but not for binding to MDCK cells, suggesting
a role for sulfatide in pore formation but not in binding to the target membrane [149].
It is of note that MAL was shown to bind sulfatide [107]. MAL and galactosylceramide
sulfotransferase, which is the enzyme that converts galactosylceramide into sulfatide,
are both regulated by thyroid hormone [150,151]. These findings are consistent with the
existence of a link between MAL and sulfatide, and raise the possibility of a connection
between MAL and ETX.
Binding and functional experiments involving MAL KD in cells positive for endoge-
nous MAL expression, and exogenous expression of MAL in cell lines that do not express
endogenous MAL, together with co-immunoprecipitation of MAL and ETX, revealed that
MAL appears to function as a receptor for ETX [152–155]. However, there is currently
no evidence of a direct protein–protein interaction between MAL and ETX. MAL KO
mice show the absence of ETX binding to tissues that bind the toxin and exhibit complete
resistance to ETX at doses 1000-fold greater than those needed to cause ETX-associated
symptoms in wild-type mice [152]. ETX sensitivity depends on oligodendrocyte expression
of MAL, as MAL-deficient oligodendrocytes are insensitive to the toxin. In addition, ETX
binding to white matter follows the spatial and temporal pattern of MAL expression [156].
ETX does not bind to wild-type zebrafish endothelial cells and, consequently, the toxin has
no effect. However, a humanized zebrafish model expressing human MAL in endothelial
cells binds to ETX and responds by producing blood–brain barrier leakage, blood vessel
stenosis, perivascular edema and blood stasis [157]. In mice, MAL expression was found
in the endothelium of some lung vessels, supporting the hypothesis that MAL is a key
element in the ETX-induced perivascular edema in the lungs [158]. ETX binding is clearly
observed in the microvasculature of the central nervous system but not in the vasculature
of peripheral organs in the mouse, indicating that ETX specifically targets the endothelial
cells of the CNS. ETX binding is dependent on MAL expression, since no binding to the
CNS microvasculature of MAL KO mice was detected. It has been proposed that the
effect of ETX on blood–brain barrier permeability in mice involves caveolae-dependent
internalization induced by the binding of ETX to MAL at the vessel lumen membrane,
and that this triggers the fusion of internalized caveolae with endosomes, the formation
of MVBs, their transport across the endothelial cell and, finally, the possible release of
exosomes into the opposite membrane, at the brain parenchyma [159].
It is notable that CHO cells, which lack endogenous MAL, expressing exogenous rat
MAL show a 10-fold increase in binding to ETX compared to those expressing human
MAL [152]. Therefore, species-specific differences in the MAL sequence contribute to the
remarkable differences in toxin-mediated pathologies observed between species, and make
humans virtually asymptomatic for the toxin. It is of note that the integrity of the last
extracellular loop of MAL is necessary for ETX binding to the cells and for cytotoxicity [152].
Therefore, this loop was proposed to form part of the site of ETX binding. However,
although there are some species-specific differences in the primary sequence of the loop
between human MAL and that of common mammals of domestic or economic interest
(Figure 3A), the loop is identical in humans and rats. This observation suggests that,
although the last extracellular loop of MAL could contribute to ETX binding, species-
specific differences in other parts of MAL might be also important (Figure S1). This
differential sensitivity should be considered when developing vaccines based on epsilon
toxin mutants [155].
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Large-scale hemolysis occurs, sometimes producing severe anemia, in patients in-
fected with C. perfringens [160–162]. ETX causes hemolysis in humans but not in other
mammals [163], suggesting that ETX-binding receptors are present on human red blood
cells but absent from those of other species. Consistent with these findings, a shorter
11-kDa MAL isoform (Figure S2) was found in human erythrocytes but not in those of
mouse or rat [164]. This isoform, which, given its size, might be devoid of exon III-encoded
sequences, appears to be the MAL species expressed by human erythrocytes [165,166].
These results are further evidence of MAL being the cellular receptor for ETX and they
identify MAL as a potential target to prevent ETX-mediated erythrocyte damage in the
case of C. perfringens infection of humans.
ETX is the third most potent toxin after botulinum and tetanus toxins [167]. The
latter are proteases that hydrolyze SNAREs (VAMP/synaptobrevin, SNAP25 and syn-
taxin) [168,169], which are proteins involved in membrane fusion during vesicular delivery
of cargo to the corresponding membrane [170,171]. Consistent with its known role in vesic-
ular transport, MAL joins SNARES as a novel membrane trafficking target of Clostridial
toxins (Figure 3B). Despite this parallelism, it should be noted that botulinum and tetanus
neurotoxins, which act on nerve terminals, have a different mechanism of action and are
involved in different membrane trafficking compartments than ETX.
9. MAL as Organizer of Condensed Membranes for Specialized Processes
Although the high-density packing of saturated lipids and cholesterol in membranes
provides the biophysical basis for membrane compartmentalization, condensed membranes
require specialized protein machinery to organize these lipids into discernible subcellular
structures and/or to ensure their functionality. For instance, caveolins organize condensed
domains into highly organized structures named caveolae, which are small flask-shaped
invaginations (60–100 nm in diameter) of the plasma membrane that are involved in signal
transduction and intracellular transport. Whereas 40–60% caveolin-1 fractionates into
DRMs [55], 100% MAL does this [98,172], indicating that MAL has a very strong propensity
for associating with this type of membrane. MAL and caveolin-1 do not associate [5], and
condensed membranes containing MAL or caveolin show distinct resistance to detergent
solubilization [5,173] and are structured distinctly: caveolin-1 is found in caveolae and in
flat membranes with no distinguishable morphology [174], whereas MAL is present only
in the latter type of membrane [25,72]. Caveolin-1 and cavin-1, which, like caveolin-1, is a
structural component of caveolae, individually sort distinct plasma membrane lipids, and
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together generate a unique lipid nano-environment selective for specific lipid headgroups
and acyl chains. It has been proposed that this membrane remodeling allows caveolae to act
as hubs that direct and guide lipid metabolism, vesicular trafficking, and signaling [175].
There is compelling evidence from various cell systems that MAL is active in the
organization of condensed membranes to make them functional:
(1) In polarized epithelial cells, HA is sorted to the apical surface and partitions into
DRMs in control cells, whereas HA transport to the apical membrane is blocked and
the association of HA with DRMs is decreased in MAL KD cells [59].
(2) The exogenous expression of MAL in epithelial A489 cells, which lack endogenous
MAL, increases the presence of HA into DRMs [59]. In addition, mutations that
prevent HA from being isolated in DRMs are more weakly associated with MAL [176].
(3) The base of primary cilia is highly condensed in wild-type MDCK cells, whereas the
degree of condensation is dramatically lower in MAL KD cells, resulting in fewer and
shorter cilia [46].
(4) Lck is transported to the plasma membrane and partitions into DRMs in control T
cells, whereas Lck is retained at the Golgi and loses its association with DRMs in
the absence of MAL expression [24]. Another effect of MAL depletion in T cells is
that the biogenesis of exosomes carrying GPI-anchored proteins, which normally
partition into DRMs, is much less extensive than in control cells [128]. Additionally,
the mistargeting of MAL from the cSMAC to the pSMAC in T cell–APC conjugates
in the presence of antigen reorganizes the structure of the IS in such a way that
condensed membranes and associated proteins, such as Lck and LAT, change their
distribution in the same manner as MAL [45].
(5) In myelin-forming cells, neurofascin 55 distributes to the paranodal domain and
is recovered from the DRM fraction in wild-type mice, but is excluded from the
paranodal zone and from DRMs in MAL KO mice [119]. In oligodendrocytes, MAL
overexpression interferes with the shift of PLP from a Triton X100-insoluble to a
TritonX-100-soluble and CHAPS-insoluble form, impeding the switch of PLP tar-
geting to myelin from transcytosis to lateral diffusion, which is associated with a
conformational change in PLP [112,114].
(6) The defects in protein transport, membrane condensation, and protein partitioning
into DRMs observed in polarized epithelial cells and T lymphocytes in MAL silenced
cells are corrected by the exogenous expression of MAL [24,59].
(7) The expression of MAL in hepatic WIF-B cells, which lack endogenous MAL expres-
sion as do normal hepatocytes, increases the partitioning of specific apical proteins
into DRMs and reroutes them from the indirect route to a direct pathway to the apical
surface [64].
(8) ETX, which associates with condensed plasma membrane regions, binds only to cells
that express MAL, and the binding is lost upon MAL KD [152–154]. Reciprocally,
the expression of MAL in cells that do not express the protein endogenously renders
condensed membranes competent for ETX binding [152,153].
(9) MAL overexpression in COS-7 cells generates giant condensed domains at the plasma
membrane that contain exogenous MAL, and restricts membrane pore expansion and
percolation produced by extraction with 1% Triton X-100 [44,177].
(10) Giant plasma membrane vesicles separate into coexisting ordered and disordered
lipid phases [32,178]. From a set of 24 structurally and functionally diverse multipass
membrane proteins, only MAL and PLP, which is a major myelin component, showed
affinity for the ordered lipid phase [41]. It is of note that MAL overexpression out-
competes PLP from these domains but PLP overexpression does not affect MAL
partitioning. This observation was interpreted as meaning that MAL and PLP compete
for a component of the ordered lipid phase present in limited amounts, and that MAL
has a higher affinity for it than does PLP [41].
Similar to the case of caveolin-1 and cavin-2 [175], the wide range of previously
evaluated observations suggests that the main function of MAL is to organize membrane
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lipids to create specific condensed membrane environments that selectively recruit specific
molecules to specialized pathways of membrane trafficking and signaling (Figure 4A).




Figure 4. MAL as organizer of raft lipids. (A) MAL remodels raft lipids to generate specialized membranes function-
ally competent for the recruitment of cargo molecules. (B) Model of MAL function in apical transport: (1) sorting 
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10. A Speculative Model of MAL Function in Membrane Trafficking
The overexpression of MAL in insect cells, which lack endogenous MAL, using
recombinant baculoviruses, causes a very large number of vesicles to accumulate in their
cytoplasm [179]. These vesicles were different in size from the caveolae-like vesicles
induced by caveolin-1 expression using the same experimental system [180], and segregated
from them, as seen in cells expressing the two proteins simultaneously [179]. Similar to the
capacity of caveolin-1 to induce caveolae-like particles in this cell system, the finding that
MAL induces extensive vesiculation could be interpreted to mean that a function of MAL
is to form vesicular carriers.
The carboxyl terminal RWKSS sequence of MAL fits with the “double lysine” con-
sensus signal (R/K(X)KXX, where X is any amino acid), which was originally found to
be involved in the retrograde transport of proteins from the Golgi apparatus to the ER
in a process involving COPI coats [181,182] and later on postulated to be a signal for
endocytosis [183]. In the MAL molecule, but not when appended to the carboxyl terminus
of the single-span transmembrane rotein CD4, the RWKSS sequence does not work as a
signal for retrograde transport to the ER. However, the substitution of the two Ser residues
by Ala diverts MAL to th endoplasmic reticulum [184]. These observations indicate that
the RWKSS sequence can act as a canonical “double ly ine” signal in protein o texts than
that of MAL, and that is probably related to this type of signal.
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The ability of mutations that inactivate double lysine signals to render MAL molecules
unable to direct HA to the apical surface suggests an important role for the RWKSS sequence
in MAL function [25]. Although the specific steps involving the RWKSS sequence are not yet
known, it could mediate MAL shuttling between different subcellular compartments and
possibly facilitates the assembly of as yet unidentified vesicular coats. We propose that MAL
compartmentalizes membranes at the Golgi, endosomes and plasma membrane to allow the
selective recruitment of specific cargo. Through its RWKSS sequence, and probably other
sorting signals, it assembles vesicular coats that lead to the formation of transport vesicles
that move between different subcellular compartments to recruit and deliver specific cargo
(Figure 4B). A role for MAL in vesicle fusion with the acceptor membrane is also proposed,
giving the similarity of its MARVEL domain to that of synaptophysin [16] and based on
the deficient fusion of plaque-transporting vesicles with the apical membrane observed in
MAL KO mouse urothelium [70].
11. Structure of the MAL Gene and Promoter Region
11.1. The MAL Gene
The human MAL gene spans approximately 28.3 kbp of the chromosome 2 band q11.1
(Figure 5A), and consists of four exons (Figure 5B) [185,186]. The first exon contains the
entire 5’ untranslated region and the region encoding the first 31 amino acids. The second
and third exons encode 56 and 42 amino acids, respectively, and the fourth exon encodes
the 24 C-terminal amino acids and contains the entire 3’ untranslated region. Splicing
between exons occurs in all the cases between the last nucleotide of a codon and the first
of the next codon. In addition to the major transcript encoding the 153-amino acid MAL
protein (sometimes referred to as MAL-a), RT-PCR analyses of human thymocytes and T
cell lines indicate the existence of minor transcripts that arise from the alternative splicing
of exons II and/or III (Figure S2), and that encode shorter isoforms (MAL b-d). Isoforms
b and c lack the second and the third transmembrane segments, respectively, and may
adopt a structure with cis-domains that loop back and exit the membrane from the same
side [186].
11.2. The MAL Promoter
CpG islands are regions of the genome that contain a large number of CpG dinu-
cleotide repeats (CpG observed/expected ratio > 0.6) and a G + C base content greater than
50%. In mammalian genomes, CpG islands typically extend for 500–1500 base pairs and are
located within, or near, gene promoter regions [187]. Epigenetics includes any process that
alters gene activity without changing the DNA sequence, and leads to modifications that
can be transmitted to daughter cells [188,189]. One of the best known epigenetic process is
DNA methylation, which involves the addition of a methyl moiety to the fifth carbon of a
cytosine residue that typically occurs in the CpG dinucleotides [190]. In normal cells, the ab-
sence of DNA methylation within CpG-rich promoter regions is associated with active gene
transcription. In cancer cells, CpG islands preceding tumor suppressor gene promoters are
often hypermethylated, which results in transcriptional blockade [191–193]. However, the
paradigm of promoter DNA methylation as a transcriptional silencing mechanism does
not always hold true [194].
The 5′-flanking region of the MAL gene features an absence of a canonical TATA
box, and the presence of a minimal promoter consisting of two binding elements for the
ubiquitous nuclear factor Sp1. These elements are located close to the transcriptional start
site, which is contained in an initiator-like sequence. Since the MAL promoter appears
to lack cis elements responsible for its characteristic tissue-restricted pattern of expres-
sion, it was postulated that mechanisms other than tissue-specific transcription factors or
specific enhancers would govern MAL expression [195]. It is also of note that the region
within about 600 bp of the 5’ proximal promoter, the first exon, and the 200-bp sequence
downstream of the first intron has a high G + C content (50.5%) and high density of CpG
dinucleotides, constituting a ~0.8-kb CpG island (Figure 5C,D).
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12. MAL in Cancer
12.1. MAL Gene Hypermethylation and Silencing Are Common Features in Many Carcinomas
The analyses of the methylation status of MAL in normal cells and in a number of
tumor specimens and tumor-derived cell lines indicate that the MAL CpG island is the sub-
ject of methylation, and that this epigenetic mechanism contributes to the downregulation
of MAL gene expression in many cancers [196–215]. The use of different methods—the
sequencing of bisulfite-treated DNA, methylation-specific PCR (MSP), quantitative MSP,
pyrosequencing, etc. [216–218]—and the analysis of different segments of the MAL CpG
island make it difficult to identify the methylation of specific CpG dinucleotides critical
to the re ulation of MAL gene expression. However, a commo feature of most of these
studies is that the methylation of the first exon and the promoter region most proximal to
the transcriptional start site is important for regulating MAL gene activity. Methylation
blocks MAL gene t anscription a d, consequently, greatly depletes MAL mRNA levels and
silences MAL protein expression.
In the various studies carried out, MAL mRNA levels were a sayed by the hybridiza-
tion of cDNA microarrays, RT-PCR, or quantitative RT-PCR. The role of methylation in
MAL gene silencing was supported by restoring MAL mRNA levels in tumor cell lines after
treatment with 5-aza-2′-deoxycytidine, which inhibits DNA methylation, combined or not
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with trichostatin A, which is an inhibitor of deacetylation [197,200–202,204,208,209,211,219–
221]. In some studies, the ability of exogenously expressed MAL to inhibit processes
related to cancer progression, such as enhanced migration, invasion or tumorigenicity,
was also analyzed to confirm the involvement of MAL in the malignant phenotype [200–
202,210,215,219]. A few studies have compared nude mice inoculated subcutaneously
with tumor cells that did or did not express exogenous MAL, and found the tumor to
be of smaller volume in the former group [202,210,219]. Immunohistochemical analysis
of the expression and distribution of MAL in some studies confirmed the silencing of
MAL expression by the hypermethylation of the MAL gene or was used, in the case of
MAL-positive tumors, to identify neoplastic cells. Unfortunately, compared with other
markers, there are few immunohistochemical assessments of MAL expression in large
numbers of cancer specimens [20,200,222–227]. MAL protein detection enables more solid
prognostic/diagnostic conclusions to be drawn than can be achieved by gene methylation
analysis alone, which involves techniques not routinely used in most Medical Pathology
Units. Table 2 summarizes the main findings from the types of tumor analyzed and shows
the potential use of MAL gene hypermethylation/MAL protein expression as a cancer
biomarker.
12.2. MAL as a Cancer Biomarker
The use of cancer biomarkers can provide information about a patient’s outcome with
a rough estimate of the decrease in survival time, the type of tumor, malignant potential,
risk of recurrence or response to a given therapy. Combined with the staging of the tumor
as the most important criterion, the use of biomarkers can guide the selection of optimal
treatment for the clinical management of the patient. There are a number of reports that
establish a correlation between MAL gene hypermethylation/MAL protein expression and
pathological characteristics of the tumors or the clinical outcome of the patients (Table 2).
Thus, whereas immunohistochemical analysis showed no significant correlation of MAL
protein expression in breast tumors with clinical-pathological variables or the disease-free
survival period when patients received chemotherapy, a separate analysis of patients
who did not receive chemotherapy showed that survival in cases of the loss of MAL
expression may have been favored by adjuvant therapy [200]. In another study, MAL
methylation frequency and methylation levels were found to be significantly higher in
Barrett’s esophagus, dysplastic Barrett’s esophagus, and esophageal adenocarcinoma than
in esophageal squamous cell carcinoma and normal esophagus. A significant correlation
was found between MAL hypermethylation and Barrett’s esophagus segment length. MAL
hypermethylation is, therefore, a common event in human esophageal adenocarcinoma
but uncommon in squamous cell carcinoma [203]. In gastric cancer, hypermethylation
of the proximal promoter region, but not of the distal region, is associated with better
disease-free survival compared with that of patients with gastric tumors unmethylated or
methylated only in the distal promoter region [199]. Epstein–Barr virus-associated gastric
cancer is associated with genome-wide DNA hypermethylation of the host CpG islands,
including the MAL gene [228]. It is interesting that the expression of exogenous MAL in
gastric cancer cell lines reduces the viral titer, probably interfering with late steps of the
viral replicative cycle such as the formation of viral particles or their budding from the
cell [228]. These results suggest that Epstein–Barr virus-induced epigenetic silencing of the
MAL gene benefits viral lytic replication, and facilitates viral propagation and spreading,
and oncogenesis.
In the prostate, MAL was identified as one of six genes whose methylation is a strong
predictor of aggressive cancer in patients categorized in the group of low-to-intermediate
risk disease [206]. Therefore, the analysis of the methylation of the MAL gene in biopsies
could enhance the identification of patients whose clinical data would otherwise lead
them to be considered of low or intermediate risk based on clinical variables [206,229].
MAL mRNA downregulation has been found in adenoid cystic carcinomas of salivary
glands [230] and in oral squamous cell carcinoma [231]. MAL expression is gradually
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lost during progression from pre-invasive lesions to squamous cell carcinoma in tobacco-
associated oral cancer [232].
The potential of MAL protein expression to discriminate between short- and long-
term survival was validated by staining a larger set of advanced serous ovarian cancers
unselected for disease outcome. This study showed that a high level of expression of the
MAL protein is associated with shorter survival [227]. MAL promoter methylation and
reduced MAL protein expression are suggested to be of diagnostic value for incipient
colorectal tumors [208,209,213,233]. In addition, MAL gene hypermethylation appears
to act as an independent prognostic predictor of survival advantage in postoperative
patients with colorectal cancer [234]. The detection of MAL promoter methylation in
cervical scrapings predicts the severity of cervical disease [201,205,214,215,235–246]. MAL
is underexpressed in the group of bladder cancer patients with bad prognosis [247]. Lower
levels of expression of MAL in Merkel cell carcinoma, which is a malignant neuroendocrine
skin tumor that, in most cases, is associated with Merkel cell polyomavirus, are significantly
associated with both unfavorable survival and the absence of Merkel cell polyomavirus in
this type of carcinoma [248].
Cisplatin is one of the most effective chemotherapeutic agents and is used for several
tumor types [249]. Epigenetic gene silencing is increasingly being recognized as contribut-
ing to the development of cisplatin resistance. The treatment with demethylating agents,
such as 5-aza-2′-deoxycytidine, resensitizes patients to platinum therapy, which is evi-
dence of the critical importance of DNA methylation in drug resistance [250,251]. MAL
transcript levels are higher in cis-platinum-resistant ovarian cell lines. MAL methylation
status and probably MAL protein expression may therefore serve as markers of platinum
sensitivity [221,252].
Unlike other types of cancers in which the involvement of MAL in cancer was in-
vestigated only with respect to the methylation status of the MAL gene or the levels
of MAL mRNA, the information about the expression of MAL in lymphomas mostly
comes from immunohistochemical or flow-cytometry analysis with anti-human MAL mAb
6D9 [20,222–226]. MAL expression in B-cell lymphomas has been investigated in both
Hodgkin and non-Hodgkin lymphomas. Most studies of the latter have been performed
on primary mediastinal lymphoma, which is classified as a subtype of diffuse large B-cell
lymphoma with a putative thymic origin [253–255]. Using differential gene expression
analysis, MAL mRNA was found to be expressed in mediastinal but not peripheral diffuse
lymphomas. Immunohistochemical analysis confirmed the selectivity of MAL expression,
revealing that approximately 64% of primary mediastinal tumors express MAL [20,222].
There is a growing body of evidence that primary mediastinal lymphoma and classic
Hodgkin lymphoma are related entities because they share clinical, histopathological, and
molecular genetic features [256]. It is of note that, as revealed by immunostaining, about
19% of classic Hodgkin lymphomas expressed MAL, and its expression correlated with
nodular sclerosis subtype. MAL expression in this type of lymphoma is an independent
risk factor for adverse outcome [226]. Therefore, MAL expression provides additional
evidence of a link between classic Hodgkin lymphoma and primary mediastinal lym-
phoma [225,226]. MAL expression is found in primary mediastinal large B-cell lymphomas,
in plasmacytoma/myeloma, and in occasional plasma cells in normal lymphoid organs, so
it was speculated that primary mediastinal large B-cell lymphomas arise from a subset of
thymic B cells that express MAL at a terminal stage of differentiation [20].
Of the T-cell neoplasms, MAL was highly expressed in lymphoblastic tumors, whereas
mature T-cell lymphomas were essentially MAL-negative [20]. In a study of patients with
mycosis fungoides, which is the most common type of cutaneous T-cell lymphoma, it
was found that MAL was overexpressed in interferon-α-resistant cell lines compared with
interferon-α-sensitive cells. Consequently, MAL expression was associated with a longer
time to remission in interferon-treated patients [223].
In conclusion, the analysis of MAL gene methylation, the measurement of MAL mRNA
levels and the immunohistochemical detection of the MAL protein are useful diagnostic
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tools for defining cancer cell subpopulations that are susceptible to becoming malignant
and to metastasizing, for distinguishing between different types of cancer, or for use
as biomarkers with prognostic value at least in some specific types of cancer. It is also
interesting that in colorectal and ovarian cancer, the analysis has also been successful when
carried out on the plasma of patients obtained from small samples of blood [257].
12.3. MAL as a Tumor Suppressor Protein
Tumor suppressor genes encode proteins, such as retinoblastoma, p53, p16INK4a,
BRCA1/BRCA2, APC, PTEN, etc., that prevent cancer by impeding the dysregulation of
pathways necessary for controlled growth and homeostasis [258]. The hypermethylation of
CpG islands of tumor suppressor genes leading to their transcriptional silencing is an early
event in carcinogenesis [259]. Tumor suppressor silencing leads to cancer by affecting a
large variety of cellular functions, such as proliferation, migration, apoptosis, DNA repair,
etc. [260].





























Breast Yes Yes Yes Yes Yes [200,207,261]
Esophagus Yes Yes Yes Yes Yes Yes [203,219,262–267]
Stomach Yes Yes Yes [199,211,228,268]




Ovary No No Yes [212,221,227,250,252,271–273]
Cervix Yes Yes Yes Yes [201,205,214,215,235–246,274–277]
Head and Neck Yes Yes Yes Yes Yes Yes [202,220,230–232,278–285]
Lung Yes Yes Yes [204,210]
Bladder Yes [247,286,287]
Prostate Yes Yes [206,229]
Kidney Yes/No *** [19]
Skin No No No [248]
Cutaneous T-cell
lymphoma No No [223]
B-cell lymphoma No No [20,222,224–226,288–292]
* DAC, 5-aza-2′-deoxycytidine; ** IHC, Immunohistochemical; ***, Dependent on the type of carcinoma.
In a number of cell lines without endogenous MAL expression derived from different
types of cancer (Table 2), the exogenous expression of MAL limits a number of cancer
progression-related cell activities, such as migration in wound-healing assays, invasion in
Matrigel®, proliferation, colony formation in soft agarose, tumorigenicity in inoculated
nude mice, and increases in the level of apoptosis relative to that in the parental cells [200–
202,210,219]. These results suggest that MAL might act as a tumor suppressor protein
preventing the development of cancer. In addition, the observation that the MAL gene
is frequently hypermethylated in most cancers, as are many very well known tumor
suppressor genes, is consistent with the silencing of the MAL gene by hypermethylation
being a necessary event in the development of cancer and with the proposed role of MAL
as a tumor suppressor protein in many organs.
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Flotillin, a protein associated with condensed membranes that is often used as a DRM
marker, fractionates into DRMs in HCC1937 cells but not in MCF10A cells, which are two
breast epithelial cell lines with and without MAL protein expression, respectively. The
ectopic expression of MAL in MCF10A cells corrects the failure of flotillin to fractionate
into DRMs and, importantly, significantly decreases cell motility compared to that of
the parental cells [200]. Keeping in mind our model of MAL function as machinery for
organizing condensed membrane environments, we propose that the MAL is a tumor
suppressor in many types of cancer. This function is essential for the normal functioning of
important trafficking and signaling pathways that incipient cancer cells need to subvert
in order to de-differentiate, migrate and invade other tissues, thereby facilitating cancer
progression.
Thymic precursor of T cells and probably some thymic B cells express MAL endoge-
nously [19,20,222,226], as do T-cell lymphoblastic leukemic cells and primary mediastinal
and some Hodgkin B-cell lymphomas [20,225,226]. In ovarian cancer, unlike most carcino-
mas in which the MAL gene is hypermethylated and there is no MAL expression, MAL
is expressed and the MAL gene is hypomethylated at the transcription start site region,
although it is methylated at an upstream region [221]. It is clear is that the proposed role of
MAL as a tumor suppressor does not extend to all types of cancer, and malignancies of
hematological cell types in which MAL is endogenously expressed, and at least those of
the ovarian epithelium, are specifically excluded. MAL may have a tumor suppressive role
in some cancers and an oncogenic role in others [293]. However, there is no direct evidence
of such an oncogenic role, since the link between high levels of MAL correlate and the poor
prognosis of B-cell lymphomas and ovarian cancer [226,227] does not necessarily mean
that MAL induces the transformation of normal cells in neoplastic cells. In any case, while
the lack of MAL might result in the loss of compaction of important platforms involved in
signaling and trafficking, thereby causing their dysregulation, the excess of MAL could
further compact those platforms in such a way that facilitates cancer progression.
13. Conclusions and Future Work
It has been more than 30 years since the first report on the MAL gene [1]. Since
then, very considerable advances have been made to understand the function of MAL in
human T lymphocytes, polarized epithelia and myelin-forming cells. MAL has come to be
recognized as an important component of the protein machinery for specialized membrane
trafficking and signaling pathways. However, there is still a long way to go before its
function is completely understood.
Proteolipids, such as the Vo sector of the eukaryotic H+-pump V-ATPase, are thought
to play a role in membrane fusion [294]. It will be interesting to investigate whether MAL is
involved in the process by which the transport vesicle is fused with the recipient membrane,
as it is believed to occur with synaptophysin. The proteolipid nature of MAL could be very
suitable for this purpose, since fusion events involve membrane regions enriched in lipids
characteristic of condensed domains [295]. In the case of urothelial cells, MAL KO mice
apparently compensate the problem in the targeting of urothelial plaque components to the
apical surface caused by the lack of MAL expression by increasing the number of transport
vesicles that fuse, albeit inefficiently, with the plasma membrane [70]. It will worthwhile
studying how other epithelia whose apical transport relies on MAL have circumvented
its absence. Little is known about the structure of the vesicles that transport proteins
with affinity for DRMs to the plasma membrane. In this regard, it will be interesting to
investigate the exact role of the MAL C-terminal RWKSS sequence in the traffic of transport
vesicles, to establish whether it is capable of assembling a coat, and to determine what
type of coat, if any, is involved. To better understand the involvement of MAL in exosome
biogenesis, it is important to elucidate whether MAL organizes condensed membranes to
form intraluminal vesicles or to sort specific cargo [130]. The involvement of MAL in the
binding of ETX to the plasma membrane is well documented, but its role as an ETX receptor
is less clear because no direct ETX–MAL interaction has yet been observed [152,153]. It
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is not clear why MAL silencing affects myelin in the CNS and the PNS in a different
manner despite the fact that it is normally expressed by the two types of myelin-forming
cells [119,120]. It is also puzzling that, despite the importance of MAL in membrane
trafficking in human T cells, MAL is absent in mouse T cells [24]. This observation raises
the possibility that a compensatory mechanism exists in these cells that has not been yet
identified. It also reminds us that, although animal models are undoubtedly quite useful
for biomedical research, studies in human cells are essential if we are to learn about human
cell functioning.
It is a challenge to find out how MAL organizes lipids to render membranes competent
for specific protein recruitment. In vitro reconstitution experiments of purified components
and the use of novel approaches are needed to answer this question. It will be highly
worthwhile to determine how the absence of MAL expression affects cellular membranes in
order to understand the tumor suppressor role of MAL and the mechanism by which MAL
silencing modifies the cell to facilitate cancer progression. In this regard, although MAL
KO mice appear normal in general and have a normal life span [119], it will be interesting
to compare whether they are more prone to developing cancer than wild-type mice when
treated with carcinogens.
Analyzing gene methylation or measuring mRNA levels are not routine practices in
most Medical Pathology Departments, since histochemistry and immunohistochemistry
are the gold standards for cancer cell characterization. MAL gene hypermethylation or
reduced MAL mRNA or protein levels are related common events during the initiation and
progression of epithelial cancers. Incorporating anti-MAL antibodies into current antibody
panels to detect MAL, either in biopsies or, as a non-invasive procedure, in human body
fluids or waste matter [296,297], might provide a prognostic/diagnostic tool for cancer
patients that can be used in routine clinical practice [257,261,270,286,287].
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